Literature DB >> 28031668

Bilateral Superficial Femoral Artery Thrombosis in a 15-Year-Old Caucasian Male with Homozygous Prothrombin G20210A Genotype and Associated Antiphospholipid Syndrome.

Uzung Yoon1, LaiLai Kwok2, Ingo Flessenkaemper3.   

Abstract

Prothrombin mutation was usually associated with other well-established predisposing factors for venous thrombosis such as antiphospholipid antibodies. Recently, even isolated prothrombin gene mutation G20210A has been reported to present severe or unusual vein thrombosis. Less clear is the role of prothrombin mutation in the formation of arterial thrombosis. We present a case of a 15-year-old healthy White male with acute bilateral femoral artery thrombosis. The patient presented with increasing left leg pain for about 1 week. He was a physically very active teenager with a new onset of leg pain aggravated by exercise. Physical examination revealed a pale and cold left foot with dorsal foot necrosis (2 × 2 cm) that started 2 days ago. In addition, he complained of moderate rest pain. No symptoms were noticed on the right lower extremity. The ankle brachial index was 0.3 on the left and 0.6 on the right. Duplex sonography showed bilateral superficial femoral artery thrombosis, which was confirmed by angiography. Subsequently, he undergoes left superficial femoral and popliteal artery lysis with rt-PA (Actilyse boehringer ingelheim, Ingelheim am Rhein, Germany) and full heparinization. Treatment was discontinued after 24 hours with no significant improvement of symptoms. Full anticoagulation with Coumadin (Bristol-Myers Squibb Company, New York, NY) and alprostadil (Prostavasin UCB, Brussels, Belgium) infusion for 2 weeks was initiated and eventually patient's symptoms improved. Laboratory testing revealed a homozygous prothrombin G20210A mutation and antiphospholipid syndrome. Homozygous prothrombin G20210A mutation in conjunction with antiphospholipid syndrome is a rare combination of coagulation disorder. Early intervention with full anticoagulation and subsequent lifelong anticoagulation should be considered in treatment strategy.

Entities:  

Keywords:  G20210A; antiphospholipid syndrome; femoral artery thrombosis; homozygous prothrombin mutation

Year:  2015        PMID: 28031668      PMCID: PMC5186255          DOI: 10.1055/s-0035-1548557

Source DB:  PubMed          Journal:  Int J Angiol        ISSN: 1061-1711


  29 in total

1.  A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome.

Authors:  Mark A Crowther; Jeff S Ginsberg; Jim Julian; Judah Denburg; Jack Hirsh; James Douketis; Carl Laskin; Paul Fortin; David Anderson; Clive Kearon; Ann Clarke; William Geerts; Melissa Forgie; David Green; Lorrie Costantini; Wendy Yacura; Sarah Wilson; Michael Gent; Michael J Kovacs
Journal:  N Engl J Med       Date:  2003-09-18       Impact factor: 91.245

2.  Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II).

Authors:  L Norgren; W R Hiatt; J A Dormandy; M R Nehler; K A Harris; F G R Fowkes
Journal:  J Vasc Surg       Date:  2007-01       Impact factor: 4.268

3.  Quality improvement guidelines for percutaneous catheter-directed intra-arterial thrombolysis and mechanical thrombectomy for acute lower-limb ischemia.

Authors:  Dimitris Karnabatidis; Stavros Spiliopoulos; Dimitrios Tsetis; Dimitris Siablis
Journal:  Cardiovasc Intervent Radiol       Date:  2011-09-01       Impact factor: 2.740

Review 4.  A patient homozygous for mutation 20210A in the prothrombin gene with venous thrombosis and transient ischemic attacks of thrombotic origin.

Authors:  A J González Ordóñez; J M Medina Rodriguez; C R Fernández Alvarez; M D Macias Robles; E Coto García
Journal:  Haematologica       Date:  1998-11       Impact factor: 9.941

5.  Recommended standards for reports dealing with lower extremity ischemia: revised version.

Authors:  R B Rutherford; J D Baker; C Ernst; K W Johnston; J M Porter; S Ahn; D N Jones
Journal:  J Vasc Surg       Date:  1997-09       Impact factor: 4.268

6.  Antiphospholipid thrombosis: clinical course after the first thrombotic event in 70 patients.

Authors:  M H Rosove; P M Brewer
Journal:  Ann Intern Med       Date:  1992-08-15       Impact factor: 25.391

Review 7.  Recurrent pulmonary embolism in a 13-year-old male homozygous for the prothrombin G20210A mutation combined with protein S deficiency and increased lipoprotein (a).

Authors:  Andrea Kosch; Ralf Junker; Cornelia Wermes; Ulrike Nowak-Göttl
Journal:  Thromb Res       Date:  2002-01-01       Impact factor: 3.944

8.  Cerebral venous sinus thrombosis in a neonate with homozygous prothrombin G20210A genotype.

Authors:  Lisa Klein; Vijay Bhardwaj; Bassam Gebara
Journal:  J Perinatol       Date:  2004-12       Impact factor: 2.521

9.  Circulating microparticles in carriers of prothrombin G20210A mutation.

Authors:  E Campello; L Spiezia; C M Radu; S Gavasso; P Zerbinati; B Woodhams; P Simioni
Journal:  Thromb Haemost       Date:  2014-05-08       Impact factor: 5.249

10.  Clinical manifestations of the prothrombin G20210A mutation in children: a pediatric coagulation consortium study.

Authors:  G Young; M Manco-Johnson; J C Gill; D M Dimichele; M D Tarantino; T Abshire; D J Nugent
Journal:  J Thromb Haemost       Date:  2003-05       Impact factor: 5.824

View more
  2 in total

1.  A Unique Case of Popliteal Artery Thrombosis in Isolated Prothrombin Gene Mutation.

Authors:  Sakthivelavan Duraipandian-Sendiladibban; Kathleen Hoban; Sumathilatha Sakthi-Velavan; Ramesh Adhikari
Journal:  Cureus       Date:  2020-12-30

Review 2.  Prothrombin G20210A Gene Mutation-Induced Recurrent Deep Vein Thrombosis and Pulmonary Embolism: Case Report and Literature Review.

Authors:  Sherif Elkattawy; Ramez Alyacoub; Kerry S Singh; Hardik Fichadiya; William Kessler
Journal:  J Investig Med High Impact Case Rep       Date:  2022 Jan-Dec
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.